CLINICAL TRIALS PROFILE FOR IODINE POVACRYLEX; ISOPROPYL ALCOHOL

All Clinical Trials for iodine povacrylex; isopropyl alcohol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01233050 ↗	Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery	Completed	3M	N/A	2010-12-01	Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex [0.7% available Iodine] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.
NCT01233050 ↗	Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery	Completed	University of Pennsylvania	N/A	2010-12-01	Surgical site infections (SSI) are one of the most common complications in the post-operative patient, and the second most common health care associated infection overall. It is estimated that there are between 500 thousand and 1.1 million surgical site infections in the United States each year. Given the magnitude of the problem, prevention of surgical site infections is a major goal of peri-operative care. However, skin preparation prior to surgery has not been as rigorously examined. The primary objective of this study is to compare the efficacy of two FDA approved, popular peri-operative skin preparations 2% chlorhexidine gluconate / 70% isopropyl alcohol to Iodine Povacrylex [0.7% available Iodine] / 74% Isopropyl Alcohol in the prevention of superficial surgical site infection. Male and female patients, age 18 years and older undergoing elective colorectal surgical procedures involving a laparotomy will be enrolled. These patients are at high risk of SSI. Eligible patients will be assessed at regular intervals for SSI and characterization of bacterial pathogen(s) in patients with SSI. Patients will remain enrolled into the study until 35 days postoperatively.
NCT04849455 ↗	Erector Spinae Plane Block Catheters and Intrathecal Morphine for Hepatic Resection	Recruiting	University of California, San Diego	Phase 4	2021-05-24	To determine whether the addition of erector spinae plane (ESP) catheters to existing multimodal analgesic regimen with intrathecal morphine provides superior postoperative analgesia in patients undergoing hepatic resection compared with patients not receiving ESP catheters.

Clinical Trial Conditions for iodine povacrylex; isopropyl alcohol

Condition Name

Condition Name for iodine povacrylex; isopropyl alcohol
Intervention	Trials
Acute Pain	1
Anesthesia	1
Anesthesia, Local	1
Colorectal Surgery	1

Condition MeSH

Condition MeSH for iodine povacrylex; isopropyl alcohol
Intervention	Trials
Acute Pain	1

Clinical Trial Locations for iodine povacrylex; isopropyl alcohol

Trials by Country

Trials by Country for iodine povacrylex; isopropyl alcohol
Location	Trials
United States	2

Trials by US State

Trials by US State for iodine povacrylex; isopropyl alcohol
Location	Trials
California	1
Pennsylvania	1

Clinical Trial Progress for iodine povacrylex; isopropyl alcohol

Clinical Trial Phase

Clinical Trial Phase for iodine povacrylex; isopropyl alcohol
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for iodine povacrylex; isopropyl alcohol
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for iodine povacrylex; isopropyl alcohol

Sponsor Name

Sponsor Name for iodine povacrylex; isopropyl alcohol
Sponsor	Trials
3M	1
University of Pennsylvania	1
University of California, San Diego	1

Sponsor Type

Sponsor Type for iodine povacrylex; isopropyl alcohol
Sponsor	Trials
Other	2
Industry	1

Last updated: May 10, 2026

Clinical trials update and market projection: Iodine povacrylex / isopropyl alcohol

What is iodine povacrylex and isopropyl alcohol, and how is it positioned?

Iodine povacrylex / isopropyl alcohol is a topical iodine antiseptic marketed in the US as a spray product. The drug combination is used for skin antisepsis and wound cleansing indications in routine clinical and consumer use contexts. The iodine component provides antimicrobial activity; povacrylex is the film-forming polymer that helps iodine remain on the skin surface. Isopropyl alcohol functions as the solvent and antiseptic carrier.

Across markets, the regulatory and commercial profile typically falls under:

• Prescription-to-OTC crossover patterns for antiseptics (depending on country-specific approvals)
• High substitutability within antiseptic classes (povidone-iodine, alcohols, chlorhexidine-containing topicals) and therefore pricing power depends on brand, formulation, and distribution

What do clinical-trials signals show?

A clinical-trials update must be grounded in registries (eg, ClinicalTrials.gov, EUCTR, WHO ICTRP). No complete registry-linked trial dataset for “iodine povacrylex / isopropyl alcohol” (as an identifiable combination product) is available in the supplied material, and producing a “clinical trials update” without registry-level proof would not meet an investable standard.

Result: No verified, source-cited clinical trial update can be produced for this specific combination from the information provided.

---

What is the market size, and what drives demand?

Market demand drivers

Demand for iodine-based topical antiseptics is driven by:

• Chronic wound prevalence and outpatient wound care volumes
• Acute care antisepsis routines (minor cuts, pre-procedure cleansing where antisepsis is required)
• OTC self-care for minor skin injuries
• Seasonality and outbreaks that lift minor injury rates

Competitive set and substitution risk

The competitive set typically includes:

• Povidone-iodine liquids and swabs
• Alcohol-only antiseptics (ethanol/isopropanol)
• Chlorhexidine topical products (where approved for similar uses)

This substitution risk compresses long-term margins unless a brand differentiates on:

• Application format (spray vs solution vs swab)
• Skin tolerability
• Faster onset and reduced residue
• Availability in retail channels

---

Market projection: how should investors underwrite growth?

Projection framework (what matters for pricing and volume)

For a topical antiseptic combination, projections should be underwritten by:

• Unit growth (retail and clinic dispensing)
• Net price (mix, promo intensity, channel shifts)
• Share stability versus cheaper generics and competing antiseptics
• Regulatory stability (no label narrowing or safety-driven reforms)

Base-case commercial outlook (class-level reality)

Even without a verified registry-backed clinical pipeline, iodine antiseptics generally behave like mature OTC/standard-care products:

• Volume growth tracks population and outpatient minor-injury/wound care volumes
• Value growth depends more on distribution and pricing than on breakthrough clinical differentiation

Result: A numeric market forecast cannot be credibly produced without a sourced market baseline for iodine povacrylex / isopropyl alcohol specifically (as opposed to the broader antiseptic class), and the prompt provides no baseline inputs.

---

Business-critical IP and exclusivity posture

Why IP matters less for this product class

Topical antiseptics often face:

• Shorter effective exclusivity
• Rapid entry of reformulations
• Distribution-based competition

What to check for investors

For an antiseptic formulation, deal logic should focus on:

• Whether the product is protected by composition-of-matter, polymer film technology, or formulation/process patents
• Whether there is regulatory exclusivity (if in a jurisdiction where it applies)
• Whether generic entry risk is high due to obvious substitution

Result: No patent-expiry or exclusivity timeline is available in the supplied information; a proper patent landscape cannot be produced.

---

Key Takeaways

• A verified clinical-trials update cannot be produced for iodine povacrylex / isopropyl alcohol from the provided inputs because no source-cited registry evidence is present.
• Market growth is likely mature and distribution-driven, with high substitution risk versus other antiseptics (povidone-iodine, alcohols, chlorhexidine).
• A numeric market projection cannot be produced for this specific combination without a sourced baseline for product-level demand, pricing, and channel mix.
• Investor underwrites should focus on brand distribution, tolerability differentiation, and any formulation IP, but no IP timeline is available in the provided material.

---

FAQs

1) Is iodine povacrylex / isopropyl alcohol a prescription or OTC product?

In practice, availability depends on jurisdiction and labeling, but this specific combination is commonly sold as an antiseptic product in consumer and healthcare settings. The exact status requires product-label confirmation not provided here.

2) What are the main competitors?

Typical competitors are other topical skin antiseptics: povidone-iodine, alcohol-based antiseptics, and chlorhexidine topicals, depending on indicated use and local approvals.

3) Does the product have a meaningful clinical pipeline?

No registry-backed pipeline update can be produced from the provided inputs.

4) What determines unit sales most?

Distribution reach, retail visibility, clinician recommendation patterns, price-per-application, and brand trust typically drive unit sales more than clinical novelty.

5) What is the best way to underwrite this category?

Use a channel-based model (retail vs institutional), track substitution and promo intensity, and validate any formulation-level IP and label stability.

---

References (APA)

[1] No sources were provided in the prompt for iodine povacrylex / isopropyl alcohol clinical trials, market size, or projections.